|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
4.820 -0.020 (-0.413%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 13,650,203 | 13.062% | 12,073,172 | 9,914,273 | 8,521,238 | 6,815,587 |
| Cost of Sales | (9,078,344) | 19.785% | (7,578,878) | (5,714,834) | (4,967,263) | (3,636,505) |
| Gross Profit | 4,571,859 | 1.726% | 4,494,294 | 4,199,439 | 3,553,975 | 3,179,082 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (192,099) | -37.455% | (307,139) | (318,235) | (247,446) | (235,213) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (1,624) | 40.728% | (1,154) | (942) | -- | -- | |
| Share of Results of Asso. & JCEs | 6,380 | -52.607% | 13,462 | 13,865 | 11,347 | 3,440 | |
| Profit / (Loss) before Taxation | 2,866,213 | 6.027% | 2,703,274 | 2,691,808 | 2,365,014 | 2,211,859 | |
| Taxation | (667,141) | 8.069% | (617,326) | (661,339) | (551,104) | (577,467) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (88,735) | -29.647% | (126,128) | (82,739) | (66,773) | (46,056) | |
| Others | (89,419) | 25.231% | (71,403) | (112,497) | (99,600) | (99,600) | |
| Profit / (Loss) Attributable to Shareholders | 2,020,918 | 7.017% | 1,888,417 | 1,835,233 | 1,647,537 | 1,488,736 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (45,075) | 17.026% | (38,517) | (27,564) | (12,996) | (79,269) |
| Depreciation & Amortisation | 508,665 | 15.070% | 442,049 | 319,464 | 269,193 | 133,106 |
| Directors' Emoluments | 13,785 | -5.782% | 14,631 | 12,354 | 12,204 | 9,640 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 107.000 | 7.000% | 100.000 | 99.000 | 96.000 | 87.000 |
| DPS (cts) | 31.740 | -- | 29.788 | 29.264 | 26.154 | 26.163 |
| Dividend Payout Ratio (%) | 29.664% | -- | 29.788% | 29.559% | 27.243% | 30.072% |
| Cash flow per share ($) | 2.640 | -- | 1.074 | (0.753) | (0.566) | (1.063) |
| NBV per share ($) | 8.248 | -- | 7.351 | 6.888 | 6.275 | 5.529 |
| Remarks: | Real time quote last updated: 14/11/2024 14:54 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,137,235 |
| %Change | 3.662% |
| EPS / (LPS) | RMB 0.600 |
| NBV Per Share (¥) | RMB 8.940 |